focus -WSS

focus

author：explore 2025-09-30 18:08:28 - browse：82

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： John Green on his newest strategy for fighting tuberculosis

leisure time

entertainment

WSS

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

UCLA team creates talking throat patch for voice disorders

Change Healthcare outage fallout shows need for new oversight

Ebola: Gilead Sciences antiviral shows promise as new treatment

President Biden's budget: Here's what you might have missed

hotspot

focus

entertainment

Apple is now the first public company to be valued at $3 trillion

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Continuity nursing helped my family in our darkest PICU moments

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Anesthesiologist group: stop taking Ozempic before surgery

Amid AI frenzy, a top HHS official's quest to create safeguards

Moonlake's readout produced a cash windfall. Risks remain

Why workplace violence is so common in health care

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

HHS secretary Becerra pressed on Change HealthCare cyberattack

explore

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Male and female sex labels in research insufficient, scientists say

entertainment

leisure time

entertainment

explore